Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus PROMETRIUM.
CURRETAB vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category C
Category C
Progestin
Progestin